Press Releases + New

Date Title and Summary View
Toggle Summary Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis View HTML
Toggle Summary Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis View HTML
Toggle Summary Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer View HTML
Toggle Summary Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
-- Galectin Therapeutics and Earle A. Chiles Research Institute --
View HTML
Toggle Summary Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders -- New Phone Number for Audio Portion of Presentation View HTML
Toggle Summary Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders View HTML
Toggle Summary Galectin Therapeutics Reports First Quarter 2013 Financial Results View HTML
Toggle Summary Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies
- Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 -
View HTML
Toggle Summary Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and Cirrhosis
-- Abstract Accepted for Presentation at the International Liver Congress 2013 --
View HTML
Toggle Summary Clinical Trial Sites for First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Announced by Galectin Therapeutics View HTML